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Abstract . The role of cell surface heparan sulfate in
herpes simplex virus (HSV) infection was investigated
using CHO cell mutants defective in various aspects of
glycosaminoglycan synthesis . Binding of radiolabeled
virus to the cells and infection were assessed in mu-
tant and wild-type cells . Virus bound efficiently to
wild-type cells and initiated an abortive infection
in which immediate-early or a viral genes were ex-
pressed, despite limited production of late viral pro-
DENTIFICATION of a particular cell surface molecule as
a receptor for a virus, or identification of multiple cell
surface molecules as alternative receptors, must be
based on evidence satisfying at least two criteria . First, pres-
ence of the receptor (or one of multiple receptors) should be
prerequisite for binding of virus to a cell and for subsequent
infection . Conversely, absence of the putative receptor(s)
should prevent specific binding of the virus to the cell and
should render the cell resistant to infection . Second, it should
be possible toshow that the virus actually interacts physically
with the cell surface molecule(s) in question . The purpose
of this paper is to report genetic evidence that the cell surface
glycosaminoglycan (GAG)', heparan sulfate, fulfills these
criteria for identification as a receptor for herpes simplex vi-
rus (HSV) .
HSV is isolated principally from humans under natural
conditions although the virus has a broad host range under
experimental conditions . A variety of laboratory animals
can be infected with the virus and most adherent vertebrate
cells grown in culture are susceptible toHSV infection . This
implies that the cell surface receptors for HSV are ubiqui-
tous and highly conserved or that different receptors may be
used for the infection of different cell types.
Two kinds of cell surface molecules have been implicated
as receptors for HSV: heparan sulfate moieties of cell surface
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teins and progeny virus . Binding of virus to heparan
sulfate-deficient mutant cells was severely impaired
and mutant cells were resistant to HSV infection . Inter-
mediate levels of binding and infection were observed
for a CHO cell mutant that produced undersulfated
heparan sulfate . These results show that heparan sul-
fate moieties of cell surface proteoglycans serve as re-
ceptors for HSV.
proteoglycans (67) and a high affinity receptor for basicFGF
(29) .
Two lines ofevidence suggested that heparan sulfate serves
as receptor for HSV. First, removal of heparan sulfate from
human cells, by enzymatic treatment, reduces the ability of
the cells to bind virus and renders the cells at least partially
resistant to HSV infection (67) . Second, the viral glycopro-
tein designated gC is principally responsible for the binding
of HSV to cells and has affinity for heparin (22), which is
closely related in structure to heparan sulfate (30) .
Two lines of evidence also suggested initially that FGF
receptors have a role inHSV adsorption to cells or in entry.
First, basic FGF was shown to inhibit HSV binding to cells
and HSV infection (29) . Second, it appeared that greater
quantities of labeled virus could bind to CHO cells trans-
fected to express a receptor for FGF than to receptor-
deficient CHO cells (29), although this result could not be
reproduced (55) .
The idea that the binding of HSV to cells might require
interaction with heparan sulfate as well as with some other
cell surface molecule (29, 67) is important to consider, in
light ofother findings . For example, the high-affinity binding
of basic FGF to cells and subsequent biological responses
require the dual interaction of basic FGF with cell surface
heparan sulfate (or soluble heparin) and other protein recep-
tors (48, 68) . In addition, the participation of neuronal cell
adhesion molecule (N-CAM) in neuronal cell-cell and cell-
substratum adhesions depends upon interactions ofN-CAM
with heparin-like molecules (10, 11) . Also, fibronectin has
specific binding domains both for cell surface heparan sulfate
and for receptors of the integrin superfamily (50) . Although
the adhesion of cells to substrata depends principally on in-
tegrin-fibronectin interactions, the reorganization of cyto-
1273skeletal components that accompanies this adhesion depends
on heparan sulfate-fibronectin interactions (33, 66) .
Here we have made use of CHO cell mutants defective in
various aspects of GAG synthesis to test further the roles of
cell surface heparan sulfate and FGF receptors in HSV infec-
tion. Most adherent vertebrate cells produce a diverse array
of proteoglycans (21, 23) . The three principal GAGS found
on cell surface proteoglycans are heparan sulfate, chondroi-
tin sulfate, and dermatan sulfate. Heparan sulfate is chemi-
cally very similar to commercial heparin, except that hepa-
rin tends to be the more highly sulfated polymer and is
produced by specialized types of cells(30) . A variety ofmu-
tant CHO cell lines isolated by Esko and colleagues (14, 15)
have been shown to have specific defects that interfere with
various aspects ofGAG biosynthesis (Table I) . CHO mutants
in complementation groups pgsA and pgsB fail to produce
GAGs because they are deficient in one of the enzymes re-
quired to form the common tetrasaccharide that is linked to
the protein core and upon which all three types of GAG are
then polymerized. CHOmutants incomplementation groups
pgsD and pgsE have defects affecting the productionofhepa-
ran sulfate but not other GAGs. Specifically, pgsD mutants
lack enzymatic activities required to form the repeating di-
saccharide unit characteristic of heparan sulfate and pgsE
mutants produce undersulfated heparan sulfate because of a
deficiency of the enzyme required to add sulfate to deacet-
ylated amino groups in the glucosamine moieties (a type of
sulfation that is not found in the other GAGs present on cell
surfaces) . Both the wild-type and mutant CHO cells used in
this study have been reported to be deficient in the high affin-
ity receptors for FGF (68).
Our results show that presence of heparan sulfate on cell
surfaces, but not other GAGs, is the principal requirement
for the binding of HSV to cells and for subsequent infection
of the cells. Moreover, the level of N-sulfation of heparan
sulfate significantly influences the amount of virus that can
bind to and infect the cells. Results presented here, coupled
with other findings presented elsewhere (43, 55), also show
that receptors for FGF do not have a role in HSV infectivity,
despite previous reports proposing this hypothesis (1, 29) . It
is possible, for reasons to be discussed, that cell surface
receptors in addition to heparan sulfate are important for
HSV penetration and infectivity. However, these other
(hypothetical) receptors remain to be identified.
Materials andMethods
Cells and Viruses
Wild-type CHO-KI cells and the GAG-déficient mutants have been de-
scribed previously (see citations in Table I). The cells were passaged in
Ham's F12 medium supplemented with 10% FBS. Human epidermoid carci-
noma No. 2 (HEp-2) cells were passaged in DME supplemented with 10%
FBS. The viruses used were HSVl(KOS), HSVI(F), and HSV2(333), and
the Indiana strain ofvesicular stomatitis virus. Titrations ofplaque-forming
units (PFU) were done on HEp-2 cells for HSV (22) and on the cells indi-
cated for vesicular stomatitis virus.
ICP4Expressionas Determined by
Immunofuorescence Assay
Cells were plated on 12-mm coverslips in 5-ml glass scintillation vials (13-
mm diam; Research Products International Corp., Mount Prospect, IL) and
incubated at 37°C overnight. The cells were inoculated with HSV in PBS
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(10 mM Na2HP04, 1.5 mM KH2PO4, 140 mM NaCl, 2.5 mM KCI, 0.5
MM M9C12, 1 mM CaCl2) supplemented with 0.1% glucose and incubated
for 6 h at 37°C (the first 2 h ofincubation wereon a shaker). The inoculum
volume was 0.1 ml and the virus concentrations were adjusted to achieve
the desired input multiplicity of infection (PFU/cell). The cells were then
treated with aperiodate-lysine-paraformaldehyde fixative (39) and permea-
bilized with 0.1% Triton X-100 in PBS. Hybridoma culture fluid containing
an anti-ICP4 mAb (either 58S [reference 56] or H640-28 [reference 25])
was diluted 1:2 with PBS containing 1% BSA (PBS-BSA) and incubated
with the cells for 30 min at roomtemperature. The cells were washed with
PBS three times to remove unbound antibodies, and then incubated with a
1:100 dilution of FITC-conjugated F(ab)2 fragments of goat anti-mouse
IgG antibodies (Organon Teknika Corp., Cappel Research Products, Dur-
ham, NC) for 30 min at room temperature. After washing, the coverslips
were mounted in medium (5 % propyl gallate, 60% glycerol in PBS) forex-
amination. For each sample, two counts of -250 cells in different fields
were made to quantitate the numbers of ICP4-positive and ICP4-negative
cells. The values given are the averages of two counts, expressed as percent
of cells that were ICP4-positive. Error bars in figures indicate the range of
values obtained for the duplicate samples.
BindingofRadiolabeled HSVto Cells
HSV virions were labeled and purified as described (8, 57) . Briefly, roller
bottles of HEp-2 cells were inoculated with virus at 3-5 PFU/cell for 2 h.
After removal of inoculum, the cells were overlaid with medium 199 sup-
plemented with 1% FBS, with or without [35S]methionine (15 pCi/ml) or
[3H]thymidine (20 uCi/ml) and incubated at 37°C for 48-72 h. When the
infected cells were labeled with [35S]methionine, themedium 199 used had
20% of the normal levels of cold methionine. Virus was harvested and
purified from infected-cell cytoplasmic lysates by centrifugation through
dextran gradients (Dextran T10; Pharmacia LKB Biotechnology Inc., Pis-
cataway, NJ). Infectious virus was quantitated by titrations on HEp-2 cells
and radioactivity was quantitated by liquid scintillation counting. Particle
numbers were determined by EM (22, 42). Most virus preparations had
titers of 108 to 109 PFU/ml. Particle/PFU ratios were usually -50:1 for
HSV1 (KOS) and HSV2(333), and about 2-5:1 for HSV1(F). Just before
use, virus was diluted 1:4 (vol/vol) in PBS, centrifuged at 40,000 g for 1 h,
and resuspended in PBS.
For thebinding experiments the cellswere plated either in 96-well round-
bottomed plates (Gibco BRL, Gaithersburg, MD), 24-well plates, or onthe
bottoms of the glass scintillation vials described above, and incubated at
37°C overnight. The confluent monolayers werepretreated with PBS-BSA
for 1 h at 37°C. The cells were then washed threetimes with PBS-BSA and
inoculated with purified labeled virus in a sufficient volume of PBS-BSA
to keep the cells covered with fluid. The cells were exposed to the labeled
virus for 6 h at 4°C on a shaker (pilot experiments revealed that 6 h was
required for the binding ofvirustoapproachequilibrium) and the cells were
then washed three times with cold PBS. If the cells had been plated on 96-
well plates, they were transferred to scintillation vials after detachment with
EDTA and scintillation fluid was added. Ifthe cells had been plated in the
scintillation vials, then scintillationfluid was simply added forthe quantita-
tion ofradioactivity bound to the cells. The values given are the averages
of duplicate samples. The results are expressed as number ofvirions bound
per cell, based on the specific activities of the virus preparations (virions
per cpm) . Error bars in figures indicate the range of values obtained.
CellKillingAssay
Cells growing in 25-cm' flasks were inoculated with virus in PBS contain-
ing 0.1% glucose. After 6 h of incubation at 37°C, the cells were detached
with trypsin-EDTA. The detached cells were then replated in 75-cm2 flasks
containing growthmedium, at -1,000 cellsper flask. After 10 d incubation,
the colonies were fixed and stained with Giemsa for quantitation.
Results
MidType CHO CellsAreSusceptible to
HSVInfection
To assess the biological significance of the binding of virus
to cells, it is important to quantitate infection in parallel with
binding. Because CHO cells were previously reported to be
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Figure 1. Expression ofan immediately-early HSV protein (ICP4)
after infection of HEp-2 cells and wild-type CHO cells with HSV1
(KOS), HSV1(F), or HSV2(333) . HEp-2 cells (o) or CHO cells
(o) were exposed to various concentrations ofvirus for 6 h at 37°C.
The cells were then fixed and stained for detection ofthe viral pro-
tein ICP4 by immunofluorescence. Thepercentage ofcells with flu-
orescent nuclei was determined. The values given for multiplicity
ofinfection (PFUper cell) are based on titrations ofPFU on HEp-2
cells.
nonpermissive for HSV replication (24), we tested whether
wild-type CHO cells are susceptible to HSV infection
nonetheless. A cell was judged to be successfully infected if
it expressed one of the immediate-early or a viral proteins,
indicating that adsorption, penetration, and uncoating of the
viral genome had occurred and that viral gene expression
had commenced. Expression of the a viral protein desig-
nated ICP4 was assessed by immunofluorescence using a
mAb specific for this viral regulatory protein. Wild-type
CHO cells and human HEp-2 cells (fully permissive for
HSV replication) were exposed to equivalent doses of each
of three different HSV strains and then processed for im-
munofluorescence at 6 h after addition of the virus.
Fig. 1 shows that all three strains of HSV induced ICP4
expression in the wild-type CHO cells but at considerably
different efficiencies compared with the ability ofeach strain
to induce ICP4 expression in HEp-2 cells. The EDso (dose
of virus required to induce ICP4 expression in 50% of cells)
was similar for HSV2(333) on both the wild-type CHO cells
and HEp-2 cells. In contrast, the ED5o for HSV1(F) on
CHO cells was more than 10 times that observed on HEp-2
cells. This differential was even greater for HSV1(KOS) . We
conclude that the wild-type CHO cells are fully susceptible
to infection by some strains of HSV (such as HSV2[333])
but that some factors present in, or absent from, the CHO
cells restrict infection by the other strains of HSV tested.
This restriction is partial and is probably not at the level of
the binding of virus to cells, based on data presented in the
next section. It seems likely, therefore, that the bottleneck for
infection by some strains of HSV is at the level of viral
penetration of the cell, uncoating of the genome, or expres-
sion of viral genes.
Expression of late viral proteins in infected CHO cells was
below normal levels and few ifany infectious progeny virions
were produced (data not shown) . It seems likely that CHO
cells do not provide the factors required for optimal expres-
sion of many HSV genes. Alternatively, CHO cells may ex-
press inhibitory factors that block expression ofintermediate
or late viral genes.
One feature of HSV infection in permissive cells is that
soluble heparin concomitantly blocks the binding of virus to
the cells and infection of the cells (22, 67) . Fig. 2 shows that
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Figure 2. Effect of heparin on HSV binding and ICP4 expression
in wild-type CHO cells. The cells were plated in scintillation vials
with and without coverslips. Samples of purified HSVl(KOS)
(['H]thymidine-labeled virus at 8.7 x 104 virions/cpM) were
mixed with various concentrations of heparin immediately before
inoculation ofthe cells. The cell number was 1.23 x 105 per vial.
Virus added was 5.6 x 109 virions per vial or 4.5 x l0° virions
per cell. Cells in vials without coverslips were exposed to virus for
6 h at 4°C. Unbound virus was then washed away and cell-bound
radioactivity was quantitated. Cells in vials with coverslips were
exposed to virus for 6 h at 37°C, for the quantitation of ICP4 ex-
pression as described in the text and legend to Fig. 1.
heparin inhibits both virus binding to and infection of wild-
type CHO cells as well . In this experiment the cells wereex-
posed to purified labeled HSV1(KOS) at a high input dose
(900 PFU/cell), in the absence or presence of heparin at the
concentrations indicated, and then replicate samples were
processed either for quantitation ofvirus binding to the cells
or for quantitation of ICP4 expression by immunofluores-
cence. Several points should be made about the results. First,
HSVI(KOS) is capable of inducing ICP4 expression in
100% of CHO cells, provided the infecting dose of virus is
large enough (compare Figs. 1 and 2). Second, the inhibition
of ICP4 expression by heparin can be fully explained by the
inhibition ofthe binding ofvirus to the cells. We assume that
the residual binding of label to the cells at the highest con-
centrations of heparin is nonspecific inasmuch as ICP4 ex-
pression was completely inhibited at these concentrations.
It should be noted that CHO cells are markedly deficient
in high affinity receptors for FGF (38, 68) and yet are suscep-
tible to HSV infection. Enhancement of FGF receptor ex-
pression by transfection of the appropriate gene into CHO
cells does not enhance susceptibility of the cells to infection
by HSV1(F) or HSV1(KOS) (55). Thus, deficiency of FGF
receptors does not account for the partial restriction of HSV
infection observed for these HSV strains in control CHO
cells. In other studies we are exploring the molecular basis
for the variability in efficiency with which different HSV
strains infect CHO cells. The focus of this study, however,
is to test the effects of CHO mutations that impair GAG bio-
synthesis on expression ofHSV receptors and on susceptibil-
ity of the cells to HSV infection.
The inhibition of HSV infection by heparin and by treatment
of cells with heparitinase (67) and the affinity of specificTable L CHO Cell Lines Used and Their Properties
Chondroitin sulfate accumulates to levels three times higher than in wild-type cells.
t The heparan sulfate produced is undersulfated by a factor of two to three.
HSV glycoproteins for heparin (22) suggested that cell sur-
face heparan sulfate may serve as receptor for HSV . To test
this possibility, the -susceptibility to HSV infection of wild-
type CHO cells and the GAG-deficient mutants (Table I) was
compared (Fig. 3). Each of the cell lines indicated was ex-
posed p a range of concentrations of HSV1(KOS), HSV
1(F), or HSV2(333)-'and infection was monitored by quan-
titating the number of cells expressing ICP4. With all three
strains ofvirus, the wild-type cellswere most susceptible to
infection and the heparan sulfate-deficient mutant cells were
least susceptible, regardless of whether the mutant cells ex-
pressed undetectable or elevated levels ofchondroitin sulfate
(Table I) . The mutant cells (pgsE-606) that produce under-
sulfated heparan sulfate had an intermediate level of suscep-
tibility to HSV infection. The difference in susceptibility of
the wild-type and heparan sulfaté-deficient cells was very
pronounced. For example, both pgsA-745 and pgsD-677
cells were almost totally resistant to concentrations of HSV
1(F) capable of infecting 100% of wild-type cells. Although
a small percentageofthe pgsA-745 and pgsD-677 cells could
be infected by HSV2(333), much higher input doses of virus
were required than was required to infect a comparable per-
centage ofwild-type cells. The altered susceptibility of cells
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Figure 3. Expression of ICP4 after infection ofwild-type CHO cells
and GAG-deficient CHO mutants with HSV1(KOS), HSV1(F), or
HSV2(333) . Wild-type and mutant cells were plated in scintillation
vials with coverslipsand then exposed to various - _ncentrations of
the virus stains indicated ICP4 expression w ititated at 6 h
after infection as described in the legend to Fig. 1. The virus input
is based on the virustiter on HEp-2 cells. The highest dose tested
for HSVI(F) (290 PFU/cell) is not included on the graph; the val-
ues obtained at 290 PFU/cell were not significantly different from
the values obtained at 145 PFU/cell.
caused by defects in heparan sulfate biosynthesis were super-
imposed on the differences in ability of the three viral strains
to infect CHO cells (Fig. 1).
The binding of HSV to mutant and wild-type CHO cells
was also assessed. Monolayer cultures of the different cell
lines were exposed to a range of concentrations of purified
radiolabeled virus at 4°C and then washed to quantitate the
amount ofvirus that remained bound to the cells. The results
presented in Figs. 4 and 5 show that there was very little, if
any, specific (heparin-inhibitable) binding to the heparan
sulfate-deficient mutants regardless of whether the mutants
produced chondroitin sulfate. The low levels of binding were
usually slightly higher for the chondroitin sulfate-produc-
ing, heparan sulfate-deficient mutant (pgsD-677) than for
the other mutants, but this did not correlate with proportion-
ately greater ICP4 expression (Fig. 3) . HSV2(333) repro-
ducibly exhibited more heparin-inhibitable binding to the
heparan sulfate-deficient cells than did the other two strains
ofvirus. This correlated with somewhat greater, but still low,
expression of ICP4 by HSV2(333) than by the other virus
strains tested. All three strains of virus exhibited intermedi-
ate levels ofbinding to the mutant cellsthat produced under-
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Figure 4. Binding ofHSVl(KOS) towild-type CHO cells andGAG-
deficient CHO mutants. Wild-type and mutant cells were plated in
96-well round-bottomed plates, and inoculated with various con-
centrations of purified PSS]methionine-labeled HSVI(KOS) (3.35
x 10^ virions/cpm). For the different cell lines, the cell numbers
ranged from 2.7 to 5.8 x 10° per well. The adsorption period was
6 h at 4°C. After unbound virus was washed away, the cells were
detached with EDTA and transferred to scintillation vials for the
quantitation of cell-bound radioactivity.
Cell type Strain Biochemical deficiency
GAGS
Heparan sulfate
produced
Chondroitin sulfate Reference
Wild-type K1 None Yes Yes
Mutant group
pgsA 745 Xylosyltransferase No No (15)
pgsB 761 Galactosyltransferase No No (16)
pgsD 677 N-acetylglucosaminyl and No Yes' (17)
glucuronosyltransferases (34)
pgsE 606 N-sulfotransferase Yes* Yes (2)
(3)ó
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Figure S. Binding of HSV to wild-type CHO cells and GAG-defi-
cient CHO mutants in the presence (o) or absence (e, w, A, v)
of heparin. Wild-type and mutant cells were plated in scintillation
vials and inoculated with purified, ['H]thymidine-labeled HSV
1(F) or HSV2(333) at different subsaturating concentrations of vi-
rus in the presence or absence of heparin (20 Ag/ml). The specific
activities of the virus preparations were 3.9 x 104 virions/cpm for
HSVl(F) and 5.0 x 104 virions/cpm for HSV2(333). For the dif-
ferent cell lines, the cell numbers ranged from 7 to 16 x 104 per
vial (HSV1[F]) and from 8 to 15 x 104 per vial (HSV2[333]).
The adsorption period was 6 h at 4°C. Cell-bound viruswas quanti-
tated as described in the legend to Fig. 2. The level of binding in
the presence of heparin was essentially the same for all cell lines;
the average heparin-inhibited values for all cell lines are repre-
sented by the open circles.
sulfated heparan sulfate. Interestingly, half-maximal binding
of HSV1(KOS) was comparable for pgsE-606 and wild-type
cells but the plateau levels differed by two- to threefold (Fig.
4) . The diminution in HSV binding to the pgsE-606 cells
correlates well with the decrease in overall sulfation ofhepa-
ran sulfate (3). The results presented in Figs. 3-5 indicate
that the resistance of the mutant CHO cellsto HSV infection
can be accounted for by the reduced levels ofbinding of HSV
to the cells.
We have not detected differences inbinding of the different
HSV strains to wild-type CHO cells that could account for
the different efficiencies with which each strain induces ICP4
expression in the wild-type cells (Figs. 1 and 5). Thus the
polymorphic viral genes that determine the efficiency of
ICP4 induction in CHO cells must influence some step be-
tween binding of virus to the cell and early viral gene ex-
pression.
Yayon et al. (68) used some of the CHO cell mutants em-
ployed in this study to transfect a gene for an FGF receptor
and to show that the binding of basic FGF to this receptor
requires the presence of cell surface heparan sulfate. Basic
FGF could bind to the transfected receptor on heparan sul-
fate-deficient cells only ifheparin was added at low concen-
trations. Because basic FGF is a heparin-binding protein, the
authors hypothesized that interaction of basic FGF with ex-
ogenous heparin or cellular heparan sulfate alters the confor-
mation of basic FGF, which enables its binding to the high
affinity receptor. An experiment was done to determine
whether low concentrations of exogenous heparin could en-
hance the binding of HSV to heparan sulfate-deficient cells
(Fig.
.6) .
Heparin ranging in concentration from 1 ng/ml to
inhibitory levels failed to enhance the binding of HSV to
heparan sulfate-deficient cells. These concentrations of hep-
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Figure 6. Effect of low-dose
heparin on binding ofHSV to
wild-typeandheparansulfate-
negative mutant CHO cells.
Wild-type and pgsA745 cells
were plated in 24-well plates
containing coverslips and ex-
posed to purified ["S]methio-
nine-labeled HSV1(KOS) (2.4
x 104 virions/cpm) mixed
with heparin at the concentra
tions indicated. Cell numbers were 4 x 105 per well. Virus added
was 1.6 x 109 virions per well. The adsorption period was for 6 h
at 4°C. After washing away unbound virus, the coverslips were
transferred to scintillation vials for the quantitation of cell-bound
radioactivity. The relatively low efficiency of virusbinding towild-
type cells in the absence ofheparinwas because 6f the larger vol-
ume of fluid used for virus adsorption (0.3' ml rather than 0.1
and resultant lower concentration of the added virus.
arin also failed to enhance infection of the heparan sulfate-
deficient cells, as assessed by testing for ICP4 expression
(results not shown). The failure of exogenous heparin to en-
hance binding of HSV suggests that the virus requires cell-
bound heparan sulfate, presumably in the form ofmembrane
proteoglycan.
Because abortive infections with HSV can be cytotoxic,
we examined the survival of wild-type CHO cells and mu-
tants afterchallenge with virus. Quantitative results were ob-
tained using a colony-forming assay. Wild-type and mutant
cells were exposed to various doses of virus. After 6 h, the
cells were detached and replaced at low density and cell
colonies were counted 10 d later. Consistent with the results
presented in Fig. l, HSV2(333) killed wild-type CHO cells
more efficiently than did HSV1(F), which in turn killed these
cellsmore efficiently than did HSVl(KOS) (data not shown).
For comparison óf the susceptibility of wild-type and mutant
cells to killing by HSV2(333), the cells were exposed to 15
or 150 PFU per cell of virus (Fig. 7) . At the highest dose
of virus used, the wild-type CHO cells were essentially all
killed whereas all of the mutants were resistant to killing by
HSV2(333). It is interesting that even the mutant,çell line.
producing undersulfated heparan sulfate was completely
resistant to killing. At the highest dose of HSV2(333) used,
-25% of the cells should have been infected, as judged by
the results of other similar experiments (Fig. 3) . Therefore
it seems likely that killing of CHO cells requires entry of
multiple virions. The possibility exists that the virion-
associated factor responsible for the immediate shut-off of
host protein synthesis (18, 49) contributes to the cytotoxicity
of HSV2(333) . Consistent with this possibility, it has been
shown that HSV2 expresses amuch more potent shut-off fac-
tor than HSV1 (19) and that full activity requires entry into
the cell of multiple virions (31) .
Mutantand Wild-type CHOCellsAre
EquallySusceptible toInfection by Vesicular
Stomatitis Virus
The heparan sulfate-deficient CHO cells are not resistant to
infection by all viruses. The results presented in Table JI
show that vesicular stomatitis virus formed plaques with
equal efficiency on wild-type and mutant CHO cells. Four
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Figure 7. Viability (colony-forming ability) of wild-type and GAG-
deficient mutant CHO cells after exposure to HSV2(333). Wild-
type and mutant cellswere plated in 25-cmz flasks and exposed to
various concentrations of HSV2(333). After 6 h of incubation at
37°C, the cells were detached and relaated at low density. After
10 d incubation, the colonies were stained and counted. The num-
ber of colonies for each sample is expressed as the percentage of
colonies obtained from mock-infected cells. The values shown are
the averages of duplicate determinations and error bars represent
the range of values obtained.
virus stocks, prepared on BHK cells or on wild-type CHO
cells, had similar titers of PFUs on all three CHO cell lines
tested. In contrast, the titers of HSV ICP4-inducing units
were so much lower on the heparan sulfate-deficient mutants
than on wild-type CHO cellsthat accurate quantitation ofthe
differences could not be done.
The results presented here provide genetic evidence that
heparan sulfate serves as cell surface receptor for HSV and
is required as receptor for the usual pathway by which this
virus attaches to and invades a cell . We show that absence
of heparan sulfate renders CHO cells deficient for HSV
receptors and resistant to HSV infection . This conclusion is
generalizable to primate cells. Although primate cell mu-
tants defective for heparan sulfate synthesis have not been de-
scribed, use of heparitinase or heparinase to selectively re-
move heparan sulfate from human or-monkey cells has
qualitatively the same effect on,.HSV binding and infection
(67) as the CHO cell mutations described here. Because
Table H. Plating Efficiencies of Vesicular Stomatitis Virus
on Wild-Type CHO Cells and Mutants
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* Virus stocks were prepared on BHK cells or on CHO-Kl cells as indicated.
Thecells were infected at 0.01 PFU/cell and incubated for 2 d in Ham's F12
medium containing 296 FBS. Themedium was cleared of cell debris and used
as the source of virus for the titrations.
$ Dilutions of each virus stock were plated on wild-type CHO-KI cells,
pgsA-745 cells, or pgsB-761 cells as indicated. Thecells were incubated for
2d in the medium described above containing 0.95% Noble agar. Plaqueswere
then counted.
soluble heparin could not enhance the binding of HSV to
heparan sulfate-deficient cells, it seems likely that the inter-
action of virus with heparin-like molecules does not serve
merely to facilitate the binding of virus to some other recep-
tor. The simplest interpretation of the findings summarized
here is that cell surface heparan sulfate serves as the HSV
receptor.
The heparan sulfate to which HSV binds must consist
largely of heparan sulfate chains covalently attached to cell
surface proteoglycans. Although free GAG chains can bind
to cells, exogenous heparin could not enhance the binding of
HSV to cells (Fig. 6) and most cell surface GAGs are cova-
lently attached to a protein core (30). CHO cells, like most
other cell types, express multiple cell surface proteoglycans
containing heparan sulfate. Recent studies indicate that a
proteoglycan related to syndecan (52) is a major cell surface
proteoglycan in CHO cells (Zhang, L., and J. D. Esko, un-
published results). CHO cells also express a proteoglycan
that is the type III receptor for transforming growth factor-0
(TGF-ß) . Interestingly, the GAG chains normally present
on this receptor (heparan sulfate and chondroitin sulfate)
are dispensable for expression of the receptor on cell sur-
faces and for binding and function of TGF-ß, as shown by
studies done with the CHO mutants pgsA-745 and pgsB-761
(9) . In contrast with TGF-ß, HSV binds to heparan sulfate
and probably not to the protein core, at least not in the ab-
sence of the heparan sulfate moieties of the proteoglycan.
For HSV, it remains to be determined whether any heparan
sulfate proteoglycan can serve as receptor or whether a par-
ticular proteoglycan is required . Specific proteoglycans may
be preferred as HSV receptors because of characteristic mod-
ifications of their heparan sulfate chains. In addition, HSV
virions may bind to diverse heparan sulfate proteoglycans
but be activated for penetration of the cell only after inter-
action with particular proteoglycans, due perhaps to inter-
actions of the virus with molecular determinants of both
heparan sulfate and the protein core or to requirement for
proteoglycans that are physically linked to other cell compo-
nents involved in viral penetration.
Characterization of the virion glycoprotein that mediates
the binding of HSV to cells supports the conclusion that
heparan sulfate is the receptor. Herold et al. (22) showed that
two of the virion glycoproteins (gB and gC) have heparin-
binding activity and that gC is principally responsible for the
binding of virions to cells. This latter conclusionwas based
on finding that gC-negative virions are impaired in ability to
bind to cells whereas absence of any of the other glycopro-
teins known to be required for HSV infectivity (gB, gD, and
gH) blocks penetration of virus into cells but not binding of
virus to cells(5, 12, 35, 36, 51) . Studies defining the molecu-
lar target of an inhibitor of HSV infection also indicate that
gC has a role in the binding of virus to cells(7, 32). Although
gC-negative virions exhibit specific infectivities less than
1/10 that of wild-type virus, there is significant residual in-
fectivity which also depends on the presence of cell surface
heparan sulfate. We have proposed that there is some redun-
dancy in viral functions that can mediate the binding of virus
to cells and that the other heparin-binding glycoprotein (gB)
may substitute for gC, albeit with lower efficiency (22).
The requirement of HSV for heparan sulfate as receptor
cannot be met by the other GAGs commonly found on cell
surfaces, such as chondroitin sulfate. The evidence includes
1278
Virus stock* Wild type
108 plaque-forming unitst
pgsA-745 pgsB-761
VSV-BHK 2.9 4.3 4.9
VSV-CHO-K1 2.5 3 .0 1 .1
VSV-CHO-Kl 3 .0 4.8 3 .1
VSV-CHO-KI 6.5 8 .5 6.0the finding that CHO cell mutants capable of expressing
chondroitin sulfate, but not heparan sulfate, are almost as
resistant to HSV binding and infection as CHO cell mutants
that fail to produce any GAGS. In addition, treatment of pri-
mate cells with enzymes capable of selectively removing
chondroitin sulfate and dermatan sulfate has no effect on sus-
ceptibility of the cells to HSV binding and infection (67).
These results imply that virion glycoproteins recognize
structural features ofheparan sulfate that are not shared with
other GAGs.
The repeating disaccharide unit ofheparan sulfate consists
of the amino sugar N-acetyl- or N-sulfo-glucosamine and a
hexuronic acid whereas the repeating disaccharide unit of
chondroitin sulfate and dermatan sulfate consists of N-ace-
tylgalactosamine and a hexuronic acid (23) . Possibly, the
amino sugar is an important determinant in specificity of the
HSV antireceptor. It is perhaps relevant in this regard that
the binding of HSV to cells can be inhibited by pretreatment
of the cells with wheat germ agglutinin (65, 69), which can
bind to N-acetylglucosamine residues. Degree of sulfation of
the heparan sulfate is also clearly an important determinant
of specificity in the interaction of HSV with cells, given the
reduced number of HSV receptors on pgsE-606 cells, which
produce undersulfated heparan sulfate. Consistent with these
findings, it was recently shown that binding of HSV to cells
is inhibited most effectively by the more highly sulfated frac-
tions of heparan sulfate or heparin and very poorly, if at all,
by chondroitin sulfate or dermatan sulfate (37) .
It is clear from the results presented here and previously
(67) that cell surface heparan sulfate is required for the bind-
ing of both serotypes of HSV (HSVl and HSV2) to cells.
Because the HSVl and HSV2 forms of gC and gB differ in
amino acid sequence (4, 13, 58, 59), the possibility exists
that there are serotype-specific differences in the structural
features of heparan sulfate required for virus binding. Such
differences could explain previous findings that the relative
binding of HSV1 and HSV2 to different cell types is not con-
stant (62, 63) . The precise requirements for interactions of
the various forms of HSV gB and gC with heparin or heparan
sulfate remain to be defined.
After the binding of HSV to a cell, penetration of virus
into the cell can occur by fusion of the virion envelope with
the cell plasma membrane (20, 44, 47, 65). The events re-
quired for viral penetration are not yet known but depend
upon the activitiesofat leastthree HSV glycoproteins desig-
nated gB, gD, and gH (5, 12, 35, 36, 51) . The possibility ex-
ists that one or more ofthese glycoproteins may interact with
a cell surface receptor distinct from heparan sulfate. If any
ofthese glycoproteins engages in interactions with receptors
other than heparan sulfate, however, these interactions must
usually occur secondary to the binding of virus to heparan
sulfate and must not be of high enough affinity to enable
efficient binding of virus to cells in the absence of heparan
sulfate. It has been proposed that gD may bind to a specific
cell surface component (6, 26-28). Absence of gD from
virions, however, does not impair binding ,of the virions to
cells; gD-negative virions are noninfectious due to improve-
ment of penetration (35). Thus, gD may interact with cell
surface components involved in fusion of the viral envelope
with the plasma membrane.
Recently it was claimed that high affinity receptors for
FGF might serve as "portals of entry" into 'cells for HSV
Shieh et al. Receptors for HSVAre Heparan Sulfate Proteoglycans
(29). This conclusion rested on findings that basic FGF
could inhibit HSV infection of endothelial cells and that la-
beled material in virus preparations bound to a greater extent
to CHO cells transfected with an FGF receptor than to con-
trol CHO cells. Subsequent studies have shown that this en-
hanced binding could not be reproduced by the authors or
us and that the FGF receptor-positive CHO cellsand control
cells were indistinguishable in susceptibility to HSV infec-
tion (55). In addition, Mirda et al. (43) showed that FGF
receptor-positive and FGF receptor-negative rat myoblasts
did not differ in susceptibility to HSV infection and that a
soluble form of the FGF receptor failed to inhibit HSV infec-
tion whereas it did inhibit basic FGF binding and biological
activity. The most likely explanations for the original results
reported by Hajjar and collaborators (1, 29) are competition
between HSV and basic FGF for binding to cell surface
heparan sulfate (43, 55) and presence ofcontaminating mate-
rial (including basic FGF) in theirlabeled virus preparations
(55) . It has been shown that other heparin-binding proteins
(such as platelet factor 4) can blockboth the binding ofHSV
to cells and infection of the cells (67).
Viral receptors for HSV and for at least two of the animal
herpesviruses - pseudorabies virus and bovine herpesvirus
type 1 - appear to be similar or related. Evidence that hepa-
ran sulfate also serves as receptor for these animal viruses
comes from findings that heparin inhibits infection and that
treatment of cells with heparitinase or heparinase reduces
the binding of virus to the cells and renders the cells at least
partially resistant to virus infection (41, 46, 53) . In addition,
both of these animal viruses encode glycoproteins that are
related to HSV gC and, for both viruses, the gC homolog
has heparin-binding activity and is principally responsible
for the binding of virus to cells (40, 41, 46, 53, 54, 64, 70).
These similarities among HSV, pseudorabies virus, and bo-
vine herpesvirus type 1 are consistent with the similarities
in biological properties and pathogenesis of the viruses (de-
spite their propensity to infect different animal species) .
With any virus, it is necessary to consider whether there
is a single pathway for viral binding and entry into cells or
multiple pathways. It seems likely that the high efficiency in-
fection of most cultured adherent cells with HSV depends
upon the presence ofcell surface heparan sulfate. This asser-
tion is based on findings that heparin inhibits infection by
HSV of many cell types and species (45, 60, 61, 67) and that
absence ofcell surface heparan sulfate renders human, mon-
key, and rodent cells resistant to HSV infection (67). On the
other hand, the heparan sulfate-deficient CHO cells could be
infected, albeit inefficiently, by HSV2(333) . This suggests
that the mutant cells may express low levels of heparin-like
molecules, that some other cell surface molecule can substi-
tute poorly for heparan sulfate, or that some alternate, but
inefficient, pathway exists for the functional binding of HSV
to cells.
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